c-Myc Targets HDAC3 to Suppress NKG2DL Expression and Innate Immune Response in N-Type SCLC through Histone Deacetylation
Peiyan Zhao(Jilin Province Tumor Hospital), Ying Cheng(First Affiliated Hospital of Xi'an Jiaotong University)
Cited by 17
Related Papers
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
|The Lancet Oncology|2023|243